drugset / Trial / NCT00005628

Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma

NCT00005628

Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent soft tissue sarcoma.

Timeline

Start
1999-11
Primary completion
2001-08
Completion
2001-08

Drugs

EvaluationDrugModalityDoseRoute
Subject vitespen Vaccine Other

Indications